ChartRow logo
Data provided bySource: Twelve Data
Share this page

INSM — Insmed Incorporated price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in INSM be worth today? →
INSM returns: By year · By month · By week · Trailing

Price data

Price
$121.16
YTD price return
-30.38%
YTD total return
-30.38%
Market cap
26.6B
Enterprise value
26B
Shares outstanding
219.4M
52W low
$90.39
52W high
$212.75
From 52W high
-43.05%
From 52W low
+34.04%
52W range
25%$90.39–$213
Beta
0.85

Volume

Rel volume
0.43×
30D volume
3.6M
30D $ vol
375.4M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$3.7M
Insider net 1Y
−$122.8M

Form 4 transactions by trade date, as filed; latest on file 2026-09-09.

Fundamentals

Sales (ttm)
1.5B
Sales/share
$6.93
EPS (ttm)
-$2.80
FCF (ttm)
-627.6M
FCF/share
-$2.86
Book value/share
$3.31
Net margin
-39.85%
ROE
-83.39%
ROA
-27.21%
Debt / equity
0.75×
Current ratio
2.86

Growth (CAGR, ttm) · 10Y

Sales
+240.25%+75.55%+54.31%n/a
Shares
+2.87%+15.31%+13.13%+13.49%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+230.77%+52.24%+36.39%n/a
Book value/share
-25.35%n/a-4.94%-0.61%
Price
-36.57%+71.76%+30.61%+23.68%
Total return
-36.57%+71.76%+30.61%+23.68%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-43.3×
Fwd P/E
172.6×
P/S (ttm)
17.5×
P/B (mrq)
36.6×
EV/Sales (ttm)
17.1×
FCF yield (ttm)
-2.36%
Buyback yield (realized, 1y)
-2.87%
Shareholder yield (realized, 1y)
-2.87%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
44th
P/B
81st

Bar = where today’s multiple sits in INSM’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
+2.62%
5D
+5.90%
1M
+25.18%
3M
-4.09%
YTD
-30.38%
1Y
-36.55%
5Y
+280.29%
1D
+2.62%
5D
+5.90%
1M
+25.18%
3M
-4.09%
YTD
-30.38%
1Y
-36.55%
5Y
+280.29%

Fundamentals#

Revenue

5Y CAGR +29.8%10Y n/mYoY +268.4%
$1.5B TTM$524.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$564M TTM−$89.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$2.80 TTM−$0.46 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$627.6M TTM−$42.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$595.6M, capex −$32M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$36.5M, capex −$5.6M

Shares (diluted)

5Y +103.9%10Y +239.4%YoY +3.3%
216.4M TTM218.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$605.6M TTM−$100.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full INSM financials →

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.

Bridgewater, NJ·1,664 employees·Biotechnology·insmed.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding INSM#

27 of the 193 ETFs ChartRow carries live hold INSM. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.8%
XBISPDR S&P Biotech ETF1.1%
IWPiShares Russell Mid-Cap Growth ETF0.6%
VHTVanguard Health Care ETF0.4%
VBKVanguard Small-Cap Growth ETF0.3%
VXFVanguard Extended Market ETF0.3%
VOTVanguard Mid-Cap Growth ETF0.3%
IWRiShares Russell Midcap ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%